• Industrial monoclonal antibody production is bottlenecked by the 3–6-month timeline needed to isolate and expand a high-yield CHO or HEK-293 clone; yields jump from ~200 mg/L to >20 g/L after rigorous single-cell cloning, but viability collapses after 30–40 passages due to metabolic and genomic drift rather than telomere exhaustion.

• A pre-print (bioRxiv 2020.03.21.990770) reports 206 neutralizing anti-SARS-CoV-2 monoclonal antibodies isolated from eight COVID-19 patients, offering a near-term pipeline for therapeutic antibodies without the traditional cell-line development delay.

• Experimental COVID-19 vaccination concepts floated included ex-vivo lymph-node bioreactor “vaccination,” low-dose UV-C–inactivated variolation, and mucosal exposure to attenuated virus, but all were dismissed as unsafe or impractical.

• Fast Optical Signal (FOS) helmets using ~100 MHz modulated near-IR LEDs and photodiodes were presented as a non-invasive brain–computer interface approach; an open archive of neuro-implant papers is maintained at http://diyhpl.us/~bryan/papers2/neuro/implants/.

• Protein engineering discussion highlighted the use of non-standard amino acids like norleucine in directed-evolution libraries to expand functional sequence space, while noting that nanopore protein sequencing and irreversible “central dogma” constraints remain key technical and theoretical limits.